You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Litigation Details for Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. (E.D. Tex. 2015)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Allergan, Inc. v. Teva Pharmaceuticals USA, Inc.
The small molecule drug covered by the patents cited in this case is ⤷  Try a Trial .
Biologic Drugs cited in Allergan, Inc. v. Teva Pharmaceuticals USA, Inc.
The biologic drugs covered by the patents cited in this case are ⤷  Try a Trial and ⤷  Try a Trial .

Details for Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. (E.D. Tex. 2015)

Date Filed Document No. Description Snippet Link To Document
2015-08-24 1 Complaint U.S. Patent No. 8,629,111, # 3 Exhibit 2 - U.S. Patent No. 8,633,162, # 4 Exhibit 3 - U.S. Patent No. … United States Patent Nos. 8,629,111 (“the ‘111 Patent”), 8,633,162 (“the ‘162 Patent”), 8,642,556 (“…Background A. Patents-In-Suit 1. U.S. Patent No. 8,629,111 73. On…‘556 Patent”), 8,648,048 (“the ‘048 Patent”), and 8,685,930 (“the ‘930 Patent”) under the Patent Laws…8,642,556, # 5 Exhibit 4 - U.S. Patent No. 8,648,048, # 6 Exhibit 5 - U.S. Patent No. 8,685,930)(Hill, Jack) External link to document
2016-04-19 130 Memorandum & Opinion several patents relating to RESTASIS— United States Patent Numbers 8,629,111 (“the ’111 patent”), 8,633,162…,162 (“the ’162 patent”), 8,642,556 (“the ’556 patent”), 8,648,048 (“the ’048 patent”), 8,685,930 (“the…“the ’930 patent”), and 9,248,191 (“the ’191 patent”). Those patents are listed in the “Orange Book,” …’930 patents. Allergan later amended its complaint to include the ’191 patent after that patent issued… I. BACKGROUND This patent infringement action arises from Abbreviated New External link to document
2016-08-05 165 Reply to Claim Construction Brief Famy Care Limited The asserted patents U.S. Patent 8,629,111 (ECF No. 155-1); …eye . . . .” See, e.g., ’162 patent, cl. 1; ’048 patent, cl. 1; ’191 patent, cl. 1. Applying the adverb… U.S. Patent 8,633,162 (ECF No. 155-2); U.S. Patent 8,642,556 (ECF… U.S. Patent 8,648,048 (ECF No. 155-4); U.S. Patent 8,685,930 (ECF…prosecution history, the patents-in-suit are not novel or innovative. Rather, the patents—which are all directed External link to document
2016-12-12 214 Memorandum & Opinion terms of the six patents at issue in this case, U.S. Patent Nos. 8,629,111 (“the ’111 patent”); 8,633,162…Petition for Inter Partes Review of U.S. Patent No. 8,629,111, Case No. IPR2016-01128 (June 3, 2016), …See ’162 patent, claim 14; ’556 patent claims 1, 13-15; ’048 patent, claims 13-16; ’191 patent, claims…8,633,162 (“the ’162 patent”); 8,642,556 (“the ’556 patent”); 8,648,048 (“the ’048 patent”); 8,685,930 (“the…the ’162 patent; claims 1, 11, and 13 of the ’556 patent; and claims 1 and 17 of the ’191 patent. The term External link to document
2017-01-11 250 Memorandum & Opinion rejected. Those applications issued as U.S. Patent Nos. 8,629,111; 8,633,162; 8,642,556; and 8,648,048. The…CsA Phase 3 Study Group.” See, e.g., U.S. Patent No. 8,629,111, col. 1, ll. 48- 52 (emphasis added).. …defrauded the U.S. Patent and Trademark Office in order to obtain allowance of the patents in suit.” Teva… U.S. Patent No. 8,685,930. Two years later, the PTO issued the last of the six related patents in suit…procedural question not specific to patent law or bearing on substantive patent law issues, so the law of the External link to document
2017-01-11 251 Memorandum & Opinion Allergan’s patent claims that contain functional limitations. See, e.g., U.S. Patent No. 8,629,111, col. … (1984), alleging infringement of U.S. Patent Nos. 8,629,111; 8,633,162; 8,642,556; 8,648,048; 8,685,…Dkt. No. 96-1 (Claims 11 and 17 of U.S. Patent No. 8,629,111, col. 15, ll. 45-48, and col. 16, ll. 16…“paragraph IV certification” that the related patents held by Allergan are “invalid or will not be infringed…Allergan’s claims of infringement for at least the patent claims that are directed to clinical efficacy. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.